Clinical Trials

Coastal Carolina Health Care, P.A. (CCHC) is participating in an observational study for Multiple Sclerosis at our New Bern Internal Medicine Specialists office. This research study is being conducted to collect real-world data on BRIUMVI (ublituximab-xiiy) administered in routine clinical practice for multiple sclerosis.

You may qualify for this study if you:

• Have been diagnosed with Multiple Sclerosis.
• Are 18 years or older with relapsing forms of Multiple Sclerosis.
• Have been prescribed Briumvi infusion but have not yet received your first infusion.

A member of our research team can provide more detail.

Qualified participants will receive all study-related care and study medication at no cost.  Financial compensation may be provided for time and travel expenses.